Skip to main content
Clinical Trials/NCT01399658
NCT01399658
Completed
Phase 2

A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO)

Dana-Farber Cancer Institute1 site in 1 country93 target enrollmentSeptember 2011

Overview

Phase
Phase 2
Intervention
Image-guided brachytherapy
Conditions
Cervical Cancer
Sponsor
Dana-Farber Cancer Institute
Enrollment
93
Locations
1
Primary Endpoint
Mean Doses Given
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.

Detailed Description

The insertion of the brachytherapy applicator will be administered in the Advanced Multimodality Image-Guided Operating (AMIGO) suite at Brigham and Women's Hospital. Subjects will undergo an MRI scan in the AMIGO suite ensuring proper placement of the applicator. Subjects may have an optional FMISO-PET scan. Subjects will have a follow-up visit including physical exam, pap smear, and MRI of the pelvis and/or PET scan 90 days after treatment. Subjects will have a follow-up visit including physical exam, pap smear, and MRI of the pelvis and/or PET scan 180 days after treatment.

Registry
clinicaltrials.gov
Start Date
September 2011
End Date
June 2016
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Martin King, MD, PhD

Prinicipal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically confirmed carcinoma of the cervix (Stage I-IVA), carcinoma of the uterus (Stage IIIB), carcinoma of the vagina (Stage I-IVA), or carcinoma of the vulva (stage I-IVA)
  • Life expectancy \> 6 months
  • MRI of the pelvis and/or PET-CT within 4 months prior to entering study

Exclusion Criteria

  • Uncontrolled intercurrent illness
  • Pacemaker, brain aneurysm clip, inner ear implant, neurostimulator, or metal fragments in the eye

Arms & Interventions

Image-Guided Brachytherapy

Image-guided brachytherapy

Intervention: Image-guided brachytherapy

Image-Guided Brachytherapy

Image-guided brachytherapy

Intervention: 3'-Deoxy-3'-18f-Fluorothymidine

Outcomes

Primary Outcomes

Mean Doses Given

Time Frame: Measured while on treatment, up to 2 months.

Doses given to the tumor, rectum, and sigmoid obtained after AMIGO-guided placement.

Study Sites (1)

Loading locations...

Similar Trials